RBC Capital Reiterates Outperform Rating for Valeant Pharmaceuticals Intl Inc (VRX)
Posted by Brady Heezen on Jan 7th, 2016 // No Comments
Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “outperform” rating reiterated by equities researchers at RBC Capital in a research note issued to investors on Thursday, StockTargetPrices.com reports.
Several other brokerages have also recently weighed in on VRX. Goldman Sachs cut Valeant Pharmaceuticals Intl from a “buy” rating to a “neutral” rating in a research report on Monday, November 2nd. Citigroup Inc. restated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, November 19th. TD Securities cut their price objective on Valeant Pharmaceuticals Intl from C$285.00 to C$260.00 and set a “buy” rating for the company in a research report on Tuesday, October 20th. Finally, Scotiabank restated a “sector outperform” rating and issued a C$250.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, October 22nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of C$224.00.
Valeant Pharmaceuticals Intl (TSE:VRX) traded down 4.53% during mid-day trading on Thursday, reaching $137.57. The company had a trading volume of 302,751 shares. The stock has a market capitalization of $47.20 billion and a price-to-earnings ratio of 79.02. Valeant Pharmaceuticals Intl has a 52 week low of $92.65 and a 52 week high of $347.84. The stock has a 50 day moving average of $133.55 and a 200 day moving average of $227.39.
In related news, Director Ron Farmer purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 21st. The shares were bought at an average price of C$193.00 per share, for a total transaction of C$193,000.00.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (TSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.